Proteomics advances for precision therapy in ovarian cancer

Marilyne Labrie, Nicholas D. Kendsersky, Hongli Ma, Lydia Campbell, Jennifer Eng, Koei Chin, Gordon B. Mills

Research output: Contribution to journalReview article

Abstract

Introduction: Due to the relatively low mutation rate and high frequency of copy number variation, finding actionable genetic drivers of high-grade serous carcinoma (HGSC) is a challenging task. Furthermore, emerging studies show that genetic alterations are frequently poorly represented at the protein level adding a layer of complexity. With improvements in large-scale proteomic technologies, proteomics studies have the potential to provide robust analysis of the pathways driving high HGSC behavior. Areas covered: This review summarizes recent large-scale proteomics findings across adequately sized ovarian cancer sample sets. Key words combined with ‘ovarian cancer’ including ‘proteomics’, ‘proteogenomic’, ‘reverse-phase protein array’, ‘mass spectrometry’, and ‘adaptive response’, were used to search PubMed. Expert opinion: Proteomics analysis of HGSC as well as their adaptive responses to therapy can uncover new therapeutic liabilities, which can reduce the emergence of drug resistance and potentially improve patient outcomes. There is a pressing need to better understand how the genomic and epigenomic heterogeneity intrinsic to ovarian cancer is reflected at the protein level and how this information could be used to improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)841-850
Number of pages10
JournalExpert Review of Proteomics
Volume16
Issue number10
DOIs
StatePublished - Oct 3 2019

Fingerprint

Proteomics
Ovarian Neoplasms
Carcinoma
Therapeutics
Protein Array Analysis
Expert Testimony
Mutation Rate
Proteins
Drug Resistance
PubMed
Epigenomics
Mass Spectrometry
Mass spectrometry
Technology
Pharmaceutical Preparations

Keywords

  • adaptive responses
  • Ovarian cancer
  • proteomics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Proteomics advances for precision therapy in ovarian cancer. / Labrie, Marilyne; Kendsersky, Nicholas D.; Ma, Hongli; Campbell, Lydia; Eng, Jennifer; Chin, Koei; Mills, Gordon B.

In: Expert Review of Proteomics, Vol. 16, No. 10, 03.10.2019, p. 841-850.

Research output: Contribution to journalReview article

Labrie, Marilyne ; Kendsersky, Nicholas D. ; Ma, Hongli ; Campbell, Lydia ; Eng, Jennifer ; Chin, Koei ; Mills, Gordon B. / Proteomics advances for precision therapy in ovarian cancer. In: Expert Review of Proteomics. 2019 ; Vol. 16, No. 10. pp. 841-850.
@article{ba77ed6496fc48aa9a984d788f9e95e6,
title = "Proteomics advances for precision therapy in ovarian cancer",
abstract = "Introduction: Due to the relatively low mutation rate and high frequency of copy number variation, finding actionable genetic drivers of high-grade serous carcinoma (HGSC) is a challenging task. Furthermore, emerging studies show that genetic alterations are frequently poorly represented at the protein level adding a layer of complexity. With improvements in large-scale proteomic technologies, proteomics studies have the potential to provide robust analysis of the pathways driving high HGSC behavior. Areas covered: This review summarizes recent large-scale proteomics findings across adequately sized ovarian cancer sample sets. Key words combined with ‘ovarian cancer’ including ‘proteomics’, ‘proteogenomic’, ‘reverse-phase protein array’, ‘mass spectrometry’, and ‘adaptive response’, were used to search PubMed. Expert opinion: Proteomics analysis of HGSC as well as their adaptive responses to therapy can uncover new therapeutic liabilities, which can reduce the emergence of drug resistance and potentially improve patient outcomes. There is a pressing need to better understand how the genomic and epigenomic heterogeneity intrinsic to ovarian cancer is reflected at the protein level and how this information could be used to improve patient outcomes.",
keywords = "adaptive responses, Ovarian cancer, proteomics",
author = "Marilyne Labrie and Kendsersky, {Nicholas D.} and Hongli Ma and Lydia Campbell and Jennifer Eng and Koei Chin and Mills, {Gordon B.}",
year = "2019",
month = "10",
day = "3",
doi = "10.1080/14789450.2019.1666004",
language = "English (US)",
volume = "16",
pages = "841--850",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Proteomics advances for precision therapy in ovarian cancer

AU - Labrie, Marilyne

AU - Kendsersky, Nicholas D.

AU - Ma, Hongli

AU - Campbell, Lydia

AU - Eng, Jennifer

AU - Chin, Koei

AU - Mills, Gordon B.

PY - 2019/10/3

Y1 - 2019/10/3

N2 - Introduction: Due to the relatively low mutation rate and high frequency of copy number variation, finding actionable genetic drivers of high-grade serous carcinoma (HGSC) is a challenging task. Furthermore, emerging studies show that genetic alterations are frequently poorly represented at the protein level adding a layer of complexity. With improvements in large-scale proteomic technologies, proteomics studies have the potential to provide robust analysis of the pathways driving high HGSC behavior. Areas covered: This review summarizes recent large-scale proteomics findings across adequately sized ovarian cancer sample sets. Key words combined with ‘ovarian cancer’ including ‘proteomics’, ‘proteogenomic’, ‘reverse-phase protein array’, ‘mass spectrometry’, and ‘adaptive response’, were used to search PubMed. Expert opinion: Proteomics analysis of HGSC as well as their adaptive responses to therapy can uncover new therapeutic liabilities, which can reduce the emergence of drug resistance and potentially improve patient outcomes. There is a pressing need to better understand how the genomic and epigenomic heterogeneity intrinsic to ovarian cancer is reflected at the protein level and how this information could be used to improve patient outcomes.

AB - Introduction: Due to the relatively low mutation rate and high frequency of copy number variation, finding actionable genetic drivers of high-grade serous carcinoma (HGSC) is a challenging task. Furthermore, emerging studies show that genetic alterations are frequently poorly represented at the protein level adding a layer of complexity. With improvements in large-scale proteomic technologies, proteomics studies have the potential to provide robust analysis of the pathways driving high HGSC behavior. Areas covered: This review summarizes recent large-scale proteomics findings across adequately sized ovarian cancer sample sets. Key words combined with ‘ovarian cancer’ including ‘proteomics’, ‘proteogenomic’, ‘reverse-phase protein array’, ‘mass spectrometry’, and ‘adaptive response’, were used to search PubMed. Expert opinion: Proteomics analysis of HGSC as well as their adaptive responses to therapy can uncover new therapeutic liabilities, which can reduce the emergence of drug resistance and potentially improve patient outcomes. There is a pressing need to better understand how the genomic and epigenomic heterogeneity intrinsic to ovarian cancer is reflected at the protein level and how this information could be used to improve patient outcomes.

KW - adaptive responses

KW - Ovarian cancer

KW - proteomics

UR - http://www.scopus.com/inward/record.url?scp=85073832234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073832234&partnerID=8YFLogxK

U2 - 10.1080/14789450.2019.1666004

DO - 10.1080/14789450.2019.1666004

M3 - Review article

C2 - 31512530

AN - SCOPUS:85073832234

VL - 16

SP - 841

EP - 850

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

SN - 1478-9450

IS - 10

ER -